stockrowGlobus Medical, Inc.
GMED Healthcare Medical Devices
Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024.
- Revenue
- −0.69%
- EPS
- +19.3%
- Free cash flow
- +10.1%
Quarter to September 2026, against a year earlier
Follow GMED
Alert me
Globus Medical, Inc. (GMED) EBITDA
Globus Medical, Inc.'s EBITDA for fiscal 2025 was $782.8M, up 18.3% from $661.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was $932.9M. Over the past ten years it has ranged from $174.9M (fiscal 2020) to $782.8M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 5 consecutive fiscal years. Globus Medical, Inc. ranks 13th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $782.8M | 18.35% |
| FY2024 | $661.4M | 84.50% |
| FY2023 | $358.5M | 18.87% |
| FY2022 | $301.6M | 23.30% |
| FY2021 | $244.6M | 39.86% |
| FY2020 | $174.9M | (21.79%) |
| FY2019 | $223.6M | 5.17% |
| FY2018 | $212.6M | 2.67% |
| FY2017 | $207.1M | 3.31% |
| FY2016 | $200.5M | 0.40% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $251.9M | 14.39% |
| Mar 2026 | $220.2M | (10.22%) |
| Dec 2025 | $245.3M | 13.89% |
| Sep 2025 | $215.4M | 41.05% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.6B |
| GMED Globus Medical, Inc. | $932.9M |
| PODD Insulet Corporation compare | $693.3M |
| PEN Penumbra, Inc. compare | $209.4M |
| BRKR Bruker Corporation compare | $158.7M |
| TXG 10x Genomics compare | −$40.4M |
| BIO.B Bio-Rad Laboratories, Inc. compare | −$61.9M |
| BIO Bio-Rad Laboratories, Inc. compare | −$61.9M |
| GKOS Glaukos Corporation compare | −$130.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on GMED
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement